Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2/anti-PD-L1 CAR T cells

A preparation of T lymphocytes that have been genetically modified to express chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) human epidermal growth factor 2 (HER2; ErbB2; HER-2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating and antineoplastic activities. Upon administration, anti-HER2/anti-PD-L1 CAR T cells target and bind to HER2- and PD-L1-expressing tumor cells, thereby inducing selective toxicity in HER2- and PD-L1-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. PD-L1 is overexpressed by many human cancer cell types and plays a key role in the downregulation of the immune system and tumor evasion from host immunity.
Synonym:dual-targeting HER2 and PD-L1 CAR T cells
HER-2/PD-L1-targeting CAR T cells
Search NCI's Drug Dictionary